

KNDD-LANDSCAPE

<https://www.neurodegenerationresearch.eu/survey/kndd-landscape/>

Title of cohort

KNDD-LANDSCAPE

Acronym for cohort

LANDSCAPE

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Richard

Name of Principal Investigator - Last name

Dodel

Address of institution -Institution

Dept. of Neurology, University Marburg

Address of institution - Street address

Rudolf-Bultmann-Str. 8

Address of institution - City

Marburg

Address of institution - Postcode

35039

Country

Germany

Website

<http://www.therapieforschung-neurologie.eu>

Contact email

Funding source

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias|Parkinson's disease

Q1b. When are studies on the above condition(s) expected to become possible?

Q2a. In a single sentence what is the stated aim of the cohort?

To investigate the development of and risk factors of dementia in patients with Parkinson's disease and Lewy body dementia

Q2b. What distinguishes this cohort from other population cohorts?

Q3a. i) Number of publications that involve use of your cohort to date

0

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years
From:

45

Q4a. Study criteria: what is the age range of participants at recruitment? To:

80

Q4b. Study criteria: what are the inclusion criteria?

Parkinson's disease; Parkinson's disease and dementia; Parkinson's disease with MCI; Lewy body dementia

Q4c. Study criteria: what are the exclusion criteria?

Other dementias

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

1,000-5,000 participants

Q6a. Please describe what measures are used to characterise participants

Detailed neuropsychometric testing; UPDRS; clinical examination; cMRI

Q6b. Are there additional measures for participants with a clinical disorder?

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If yes please specify

Q7. What is the study design (select all that apply)?

Prospective cohort|Longitudinal

Q8. Are your cases matched by

Age

Q9a. Does your study include a specialised subset of control participants?

Yes

Q9b. If your study includes a specialised subset of control participants please describe

Q10a. i) Please enter the data collection start date

01/01/2010

Q10a. ii) Please enter the data collection end date

Q10a. iii) Is data collection for this study

Data collection ongoing|Data analysis ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Q11. Is data collected

Other please specify here

Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

Q13a. Please give information on the format and availability of data stored in a database (1)

% available

Q13a. Please give information on the format and availability of data stored in a database (2)

% available

Q13a. Please give information on the format and availability of data stored in a database (3)

% available

Q13a. Please give information on the format and availability of data stored in a database (4)

% available

Other (please specify)

% available

Q13b. Please give information on the format and availability of data held as individual records (1)

% available

Q13b. Please give information on the format and availability of data held as individual records (2)

% available

Q13b. Please give information on the format and availability of data held as individual records (3)

% available

Q13b. Please give information on the format and availability of data held as individual records (4)

% available

Please specify language used

Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Q15. What data sharing policy is specified as a condition of use?

Data to be made publicly available immediately

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below:

Q16b. ii) In what form are tissues/samples/DNA supplied?

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Q17. Is information on biological characteristics available to other groups?

Yes, for all the cohort

Number of Patients

% of total cohort

Types:

Population Cohorts

Member States:

Germany

Diseases:

Alzheimer's disease & other dementias, Parkinson's disease & PD-related disorders

Years:

2016

Database Categories:

N/A

Database Tags:

N/A